Durable Response Rate
ODOMZO® (sonidegib) | Efficacy Data
Comparing Outcomes in Patients with Recurrent or Refractory Ovarian Cancer Managed with 1 of 2 Versions of Pegylated Liposomal Doxorubicin at an Academic Medical Center
Overall Response Rate of 76% in Advanced Melanoma Patients with Dynavax's SD-101 in Combination with KEYTRUDA® (pembrolizumab); Data Presented Today at the 2019 ASCO Annual Meeting | Dynavax Technologies Corporation
The overall response rate | Download Table
Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial | Nature Medicine
Efficacy endpoints in Oncology
COTELLIC® (cobimetinib) + ZELBORAF® (vemurafenib) Objective Response Rate
Response rates Overall response rate and depth of response according to... | Download Scientific Diagram
Forest plot of the comparison of overall response rate (ORR).
BRAFTOVI + cetuximab | Overall Response Rate | ORR | BEACON CRC
Objective response rate assessment in oncology: Current situation and future expectations
Overall Response Rates - WM | IMBRUVICA® (ibrutinib) HCP
Updated Data for Indoximod Plus KEYTRUDA® (pembrolizumab) Demonstrate Improvement of Response Rate for Patients with Advanced Melanoma | Business Wire
Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know
Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know
Efficacy | Tivdak® (tisotumab vedotin-tftv)
Efficacy | BALVERSA® (erdafitinib) HCP
Response Rates for Waldenström Macroglobulinemia Improve With Use of New First-Line, Better-Tolerated Treatments - U.S. Medicine
RESONATE-2 - Overall Response Rate | IMBRUVICA® (ibrutinib) HCP
Overall response rate | Download Table
Efficacy | BALVERSA® (erdafitinib) HCP
Cell therapy doubles survival, response rates in advanced melanoma
Efficacy Data | KYMRIAH® (tisagenlecleucel) for DLBCL | HCP
